deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03368196

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Phase 1, Multicenter, Open-label Study of DS-8201a to Assess Safety and Pharmacokinetics in Subjects With HER2-Positive Advanced and/or Refractory Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer

Sponsor: AstraZeneca

Conditions Adenocarcinoma, Gastric Neoplasm, Breast
Interventions DS-8201a
Updated 17 times since 2017 Last updated: Nov 2, 2022 Started: Apr 2, 2018 Primary completion: Sep 14, 2018 Completion: Sep 28, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Adenocarcinoma, Gastric and Neoplasm, Breast and is currently completed. AstraZeneca leads this study, which shows 17 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Jan 2019 · 5 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Aug 2019 · 4 months · monthly snapshot~Aug 2019 – ~Aug 2020 · 12 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Mar 2024 · 14 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2023 — Mar 2024 [monthly]

    Completed PHASE1

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 12 earlier versions

  1. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1

  2. Jan 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  6. Aug 2019 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

  7. Apr 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1

  8. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1

  9. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1

  10. Aug 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  11. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  12. Dec 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations